Can a Two-Pronged antibody boost Chemo's power against lung cancer?
NCT ID NCT06944470
First seen Jul 24, 2026 · Last updated Jul 24, 2026
Summary
This phase 2 trial is testing whether adding an experimental bispecific antibody called JS207—which targets both PD-1 and VEGF—to standard platinum-based chemotherapy can improve outcomes for people with stage II-III non-small cell lung cancer (NSCLC). Participants will receive the combination before surgery or definitive chemoradiation, followed by additional JS207 afterward. The study aims to see if this approach increases the rate of complete tumor disappearance (pathologic complete response) and delays cancer progression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental bispecific antibody called JS207 that targets PD-1 and VEGF, combined with platinum-based chemotherapy
- What this could lead to
- If successful, this combination could improve the chance of eliminating lung cancer before surgery or radiation, potentially leading to better long-term outcomes for people with stage II-III NSCLC.
- What could go wrong
- This is an early phase 2 trial with a small number of participants, so the benefits and risks are not yet well understood. The combination may cause significant side effects, and it is too early to know if it will improve survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, 510080, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug combo aims to shrink tough lung tumors
- New drug combo aims to outsmart lung cancer that resists immunotherapy
- Blood test may let cancer patients take safe breaks from immunotherapy
- New targeted pill aims to shrink lung tumors in patients with common gene mutation
- Lung cancer drug interaction study aims to uncover safe dosing
- New PET scan could predict who benefits from targeted lung cancer therapy